Mirae Asset Global Investments Co. Ltd. Has $59.59 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Mirae Asset Global Investments Co. Ltd. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.4% during the fourth quarter, HoldingsChannel reports. The firm owned 77,204 shares of the biopharmaceutical company’s stock after acquiring an additional 14,635 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $59,591,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Meyer Handelman Co. lifted its position in shares of Regeneron Pharmaceuticals by 0.6% during the 4th quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock worth $2,221,000 after buying an additional 18 shares during the last quarter. CoreCap Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 9.2% during the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 20 shares during the last quarter. Strait & Sound Wealth Management LLC increased its position in Regeneron Pharmaceuticals by 3.5% during the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock worth $353,000 after purchasing an additional 21 shares in the last quarter. Parkside Financial Bank & Trust lifted its stake in Regeneron Pharmaceuticals by 14.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 21 shares during the last quarter. Finally, MAI Capital Management lifted its stake in Regeneron Pharmaceuticals by 2.1% in the 3rd quarter. MAI Capital Management now owns 1,028 shares of the biopharmaceutical company’s stock valued at $578,000 after purchasing an additional 21 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 3,774 shares of company stock worth $2,942,738. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.1%

NASDAQ REGN opened at $746.00 on Friday. The firm has a market capitalization of $78.87 billion, a PE ratio of 17.95, a price-to-earnings-growth ratio of 2.00 and a beta of 0.40. The business’s 50-day moving average price is $766.33 and its two-hundred day moving average price is $724.12. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the company earned $12.07 earnings per share. The firm’s revenue was up 2.5% compared to the same quarter last year. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.05%.

Analysts Set New Price Targets

A number of brokerages have weighed in on REGN. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a research report on Monday, March 2nd. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, April 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. Guggenheim lifted their price target on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $811.96.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.